Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Janja Ocvirk) .

1 - 10 / 124
First pagePrevious page12345678910Next pageLast page
1.
2.
Vismodegib in locally advanced basal cell carcinoma in Slovenia
Tanja Mesti, Maša Sever, Janja Ocvirk, 2022, original scientific article

Abstract: Background: Vismodegib is a first-in-class inhibitor of the hedgehog pathway for treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC. Objectives: The purpose of this study is to report outcomes of patients with laBCC, with basal cell carcinoma nevus syndrome (Gorlin Goltz syndrome [G-G Syn]) treated with vismodegib in routine clinical practice in Slovenia in 8.3-year period. Methods: In this retrospective cohort study, we analyzed baseline characteristics, outcomes, and treatment-related adverse events from locally advanced BCC. The patients were divided into two cohorts: 39 laBCC or multiple BCC patients and 7 patients with G-G Syn who were treated with vismodegib from November 2012 till January 2021. Results: During 100-month period, 46 patients were diagnosed with laBCC (26), multiple BCC (13), and G-G Syn (7), all inappropriate for surgery or radiotherapy. Baseline characteristics: median age was 72.8 years in laBCC + multiple BCC cohort and 47.4 years in G-G Syn cohort. The objective response rate was 80% in laBCC + multiple BCC and 86% in G-G Syn cohort. Disease control rate (DCR) was 95% in laBCC + multiple BCC and 100% in G-G Syn cohort. Median duration of treatment was 9.9 months (range: 1.5-43.1) in laBCC and multiple BCC cohort and 19.5 months (range: 3.6-94.1) in G-G Syn cohort. Majority of treatment-emergent adverse events (TEAEs) in laBCC or multiple BCC cohort were grade 1 or 2 (96%), only 4% of AEs were grade 3. Majority of TEAEs in G-G Syn cohort were also grade 1 or 2 (87%), 13% of AEs were grade 3. No grade 4 or 5 vismodegib-related AEs were reported. Conclusion: Vismodegib has shown meaningful efficacy with DCR from 95% to 100% in patients with laBCC, multiple BCC, and G-G Syn in Slovenia. TEAEs were successfully alleviated with multidisciplinary approach and early supportive care.
Keywords: basal cell carcinoma, early supportive care, Gorlin Goltz syndrome, multidisciplinary approach
Published in DiRROS: 07.09.2022; Views: 116; Downloads: 44
.pdf Full text (448,27 KB)
This document has many files! More...

3.
4.
Sodobna sistemska onkološka terapija
Janja Ocvirk, 2022, published scientific conference contribution

Keywords: citostatiki, tarčna zdravila, hormonska zdravila, imunoterapija
Published in DiRROS: 01.09.2022; Views: 81; Downloads: 33
.pdf Full text (117,12 KB)
This document has many files! More...

5.
Izbrane teme iz internistične onkologije za zdravnike družinske medicine, Ljubljana, junij 2022
2022, proceedings of peer-reviewed scientific conference contributions (domestic conferences)

Keywords: internistična onkologija, družinska medicina, onkološko zdravljenje
Published in DiRROS: 30.08.2022; Views: 122; Downloads: 30
.pdf Full text (14,13 MB)

6.
Tečaj osnov dermatoskopije za onkologe, Onkološki inštitut Ljubljana, 15.-16. junij 2022
2022, other monographs and other completed works

Keywords: dermatoskopija, koža, struktura kože, klinična praksa
Published in DiRROS: 18.08.2022; Views: 97; Downloads: 34
.pdf Full text (33,72 MB)

7.
Dnevnik zdravljenja z zdravilom regorafenib
Janja Ocvirk, Martina Reberšek, Neva Volk, Tanja Mesti, Marko Boc, Marija Ignjatović, Nežka Hribernik, 2022, dictionary, encyclopaedia, lexicon, manual, atlas, map

Keywords: kemoterapija, rak debelega črevesa in danke, gastrointestinalni tumorji
Published in DiRROS: 14.07.2022; Views: 123; Downloads: 54
.pdf Full text (2,48 MB)

8.
Sluznični melanom s prisotno c-KIT mutacijo – prikaz primera : Elektronski vir
Katja Leskovšek, Janja Ocvirk, 2022, published scientific conference contribution

Keywords: melanom, rak kože, kemoterapija
Published in DiRROS: 11.04.2022; Views: 159; Downloads: 80
.pdf Full text (797,47 KB)

9.
Sistemsko zdravljenje napredovalega melanoma – imunoterapija : Elektronski vir
Janja Ocvirk, 2022, published scientific conference contribution

Keywords: melanom, rak kože, sistemsko zdravljenje
Published in DiRROS: 11.04.2022; Views: 184; Downloads: 71
.pdf Full text (450,90 KB)

10.
Obravnava bolnikov s presajeno ledvico in ne-melanomskim rakom kože : Elektronski vir
Tomaž Milanez, Miha Arnol, Janja Ocvirk, 2022, published scientific conference contribution

Keywords: melanom, rak kože, presaditev ledvice
Published in DiRROS: 08.04.2022; Views: 215; Downloads: 83
.pdf Full text (301,30 KB)

Search done in 0.67 sec.
Back to top